It’s useful to review deal trends periodically to gain insight in how behaviours are changing from the perspective of numbers and value of deals as well as how emphasis shifts from one therapeutic area to another. The majority of small and mid-size development companies will still seek a deal with one
of the major pharmaceutical companies in order to commercialise their asset.